Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
137.50
+6.50 (4.96%)
At close: Mar 10, 2026

TPE:6919 Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
203,05094,36523,5407,528--
Upgrade
Market Cap Growth
92.34%300.87%212.69%---
Upgrade
Enterprise Value
196,53884,68522,6946,297--
Upgrade
Last Close Price
131.0061.5019.136.11--
Upgrade
PS Ratio
5803.082123.71604.64587.23--
Upgrade
PB Ratio
21.659.736.296.47--
Upgrade
P/TBV Ratio
21.659.736.296.47--
Upgrade
EV/Sales Ratio
-1905.86582.91491.18--
Upgrade
Debt / Equity Ratio
0.000.000.010.030.062.81
Upgrade
Net Debt / Equity Ratio
-0.69-1.00-0.99-0.93-0.870.80
Upgrade
Net Debt / EBITDA Ratio
9.4013.887.483.582.60-0.39
Upgrade
Net Debt / FCF Ratio
15.5118.148.534.214.44-0.75
Upgrade
Asset Turnover
0.000.010.020.010.030.05
Upgrade
Inventory Turnover
2.657.045.992.252.412.89
Upgrade
Quick Ratio
112.80183.4250.4823.0415.001.45
Upgrade
Current Ratio
114.40184.0250.8123.4115.261.72
Upgrade
Return on Equity (ROE)
-5.11%-8.76%-19.92%-31.64%-64.89%-528.22%
Upgrade
Return on Assets (ROA)
-4.64%-6.59%-12.68%-20.53%-30.68%-33.22%
Upgrade
Return on Capital Employed (ROCE)
-7.60%-7.40%-13.70%-27.00%-34.30%-64.90%
Upgrade
Earnings Yield
-0.24%-0.62%-2.08%-3.80%--
Upgrade
FCF Yield
-0.21%-0.56%-1.84%-3.41%--
Upgrade
Buyback Yield / Dilution
-13.14%-15.40%-5.77%-27.35%-23.49%-6.52%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.